Home
>
US Stocks
>
Mersana Therapeutics Inc
Mersana Therapeutics Inc
MRSN

Mersana Therapeutics Inc

$8.527.84%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
8.82
Today Low/High
8.45 / 8.82
52 Week Low/High
$10.34 / $29.09
Market Cap
$842.48M

Company Details

Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana's lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersana's second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana's customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company's early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Company's Immunosynthen platform. In addition, multiple partners are using Mersana's Dolaflexin platform to advance their ADC pipelines.
Organisation
Mersana Therapeutics Inc
Headquaters
Cambridge, Massachusetts, US
Employees
110
Industry
Health Technology
CEO
Anna Protopapas

Discover more

Frequently Asked Questions

What is Mersana Therapeutics Inc share price today

Can Indians buy Mersana Therapeutics Inc shares?

How can I buy Mersana Therapeutics Inc shares from India?

Can Fractional shares of Mersana Therapeutics Inc be purchased?

What are the documents required to start investing in Mersana Therapeutics Inc stocks?

We are a SEBI registered investement advisor